Abstract
Nearly 2 out of 3 patients with venous thromboembolism (VTE) and 1 out of 4 patients with atrial fibrillation (AF) will die within the year. Whether, when, and how to manage anticoagulation at the end of life requires many trade-offs. Patients and clinicians must balance symptom burden, greatly elevated bleeding and thrombosis risks, competing comorbidities and medications, and changing goals over time. This review uses cases of VTE and AF to present a framework for care that draws upon existing disease-specific data and cutting-edge palliative care science. It reviews strategies for the difficult task of estimating a patient's prognosis, characterizes the enormous public health burden of anticoagulation in serious illness, and analyzes the data on anticoagulation outcomes among those with limited life expectancy. Finally, an approach to individualized decision-making that is predicated on patients' priorities and evidence-based strategies for starting, continuing, or stopping anticoagulation at the end of life are presented.
References
1.
Boyd
C
, Smith
CD
, Masoudi
FA
, et al. Decision making for older adults with multiple chronic conditions: executive summary for the American Geriatrics Society guiding principles on the care of older adults with multimorbidity
. J Am Geriatr Soc
. 2019
;67
(4
):665
-673
.2.
Gill
TM
. The central role of prognosis in clinical decision making
. JAMA
. 2012
;307
(2
):199
-200
.3.
Yourman
LC
, Lee
SJ
, Schonberg
MA
, Widera
EW
, Smith
AK
. Prognostic indices for older adults: a systematic review
. JAMA
. 2012
;307
(2
):182
-192
.4.
Lee
SJ
, Lindquist
K
, Segal
MR
, Covinsky
KE
. Development and validation of a prognostic index for 4-year mortality in older adults
. JAMA
. 2006
; 295
(7
):801
-808
.5.
6.
Smith
AK
, White
DB
, Arnold
RM
. Uncertainty—the other side of prognosis
. N Engl J Med
. 2013
;368
(26
):2448
–2450
.7.
Colilla
S
, Crow
A
, Petkun
W
, Singer
DE
, Simon
T
, Liu
X.
Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population
. Am J Cardiol
. 2013
;112
(8
):1142
-1147
.8.
Heit
JA
. Epidemiology of venous thromboembolism
. Nat Rev Cardiol
. 2015
;12
(8
):464
-474
.9.
Siontis
KC
, Gersh
BJ
, Weston
SA
, et al. Associations of atrial fibrillation after noncardiac surgery with stroke, subsequent arrhythmia, and death: a cohort study
. Ann Intern Med
. 2022
;175
(8
):1065
-1072
.10.
Ouellet
GM
, Fried
TR
, Gilstrap
LG
, et al. Anticoagulant use for atrial fibrillation among persons with advanced dementia at the end of life
. JAMA Intern Med
. 2021
;181
(8
):1121
-1123
.11.
Engbers
MJ
, Van Hylckama Vlieg
A
, Rosendaal
FR
. Venous thrombosis in the elderly: incidence, risk factors and risk groups
. J Thromb Haemost
. 2010
;8
(10
):2105
-2112
.12.
Søgaard
KK
, Schmidt
M
, Pedersen
L
, Horváth-Puhó
E
, Sørensen
HT
. 30-year mortality after venous thromboembolism: a population-based cohort study
. Circulation
. 2014
;130
(10
):829
-836
.13.
Noble
S
, Banerjee
S
, Pease
NJ
. Management of venous thromboembolism in far-advanced cancer: current practice
. BMJ Support Palliat Care
. 2022
;12
(e6
):e834
–e837
.14.
Holmes
HM
, Min
LC
, Yee
M
, et al. Rationalizing prescribing for older patients with multimorbidity: considering time to benefit
. Drugs Aging
. 2013
;30
(9
):655
-666
.15.
Lee
SJ
, Leipzig
RM
, Walter
LC
. Incorporating lag time to benefit into prevention decisions for older adults
. JAMA
. 2013
;310
(24
):2609
-2610
.16.
Lip
GYH
, Nieuwlaat
R
, Pisters
R
, Lane
DA
, Crijns
HJGM
. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation
. Chest
. 2010
;137
(2
):263
–272
.17.
Kearon
C.
Natural history of venous thromboembolism
. Circulation
. 2003
;107
(23 suppl 1
):I22
-I30
.18.
Stevens
SM
, Woller
SC
, Kreuziger
LB
, et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report – executive summary
. Chest
. 2021
;160
(6
):e545
-e608
.19.
20.
Shah
SJ
, Singer
DE
, Fang
MC
, Reynolds
K
, Go
AS
, Eckman
MH
. Net clinical benefit of oral anticoagulation among older adults with atrial fibrillation
. Circ Cardiovasc Qual Outcomes
. 2019
;12
(11
):e006212
.21.
Okumura
K
, Akao
M
, Yoshida
T
, et al. Low-dose edoxaban in very elderly patients with atrial fibrillation
. N Engl J Med
. 2020
;383
(18
):1735
-1745
.22.
Lafaie
L
, Poenou
G
, Hanon
O
, et al; RIETE
Investigators
. Anticoagulation and venous thromboembolism in patients aged 90 years and older: data from the RIETE registry
. J Am Geriatr Soc
. 2024
;72
(1
):113
-125
.23.
Key
NS
, Khorana
AA
, Kuderer
NM
, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update
. J Clin Oncol
. 2023
;41
(16
):3063
-3071
.24.
Lyman
GH
, Carrier
M
, Ay
C
, et al. American Society of Hematology 2021 Guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer
. Blood Adv
. 2021
;5
(4
):927
-974
.25.
Streiff
MB
, Holmstrom
B
, Angelini
D
, et al. Cancer-associated venous thromboembolic disease, version 2.2021, NCCN Clinical Practice Guidelines in Oncology
. J Natl Compr Canc Netw
. 2021
;19
(10
):1181
-1201
.26.
Noble
S
, Johnson
MJ
. Management of cancer-associated thrombosis in people with advanced disease
. BMJ Support Palliat Care
. 2012
;2
(2
):163
-167
.27.
Francis
CW
, Kessler
CM
, Goldhaber
SZ
, et al. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN study
. J Thromb Haemost
. 2015
;13
(6
):1028
-1035
.28.
White
C
, Noble
SIR
, Watson
M
, et al. Prevalence, symptom burden, and natural history of deep vein thrombosis in people with advanced cancer in specialist palliative care units (HIDDen): a prospective longitudinal observational study
. Lancet Haematol
. 2019
;6
(2
):e79
-e88
.29.
Tardy
B
, Picard
S
, Guirimand
F
, et al. Bleeding risk of terminally ill patients hospitalized in palliative care units: the RHESO study
. J Thromb Haemost
. 2017
;15
(3
):420
-428
.30.
Klok
FA
, van der Hulle
T
, den Exter
PL
, Lankeit
M
, Huisman
MV
, Konstantinides
S.
The post-PE syndrome: a new concept for chronic complications of pulmonary embolism
. Blood Rev
. 2014
;28
(6
):221
-226
.31.
Galanaud
JP
, Monreal
M
, Kahn
SR
. Epidemiology of the post-thrombotic syndrome
. Thromb Res
. April 2018
;164
:100
-109
.32.
Rubin
EB
, Buehler
AE
, Halpern
SD
. States worse than death among hospitalized patients with serious illnesses
. JAMA Intern Med
. 2016
;176
(10
):1557
-1559
.33.
Fried
TR
, Van Ness
PH
, Byers
AL
, Towle
VR
, O'Leary
JR
, Dubin
JA
. Changes in preferences for life-sustaining treatment among older persons with advanced illness
. J Gen Intern Med
. 2007
;22
(4
):495
-501
.34.
Auriemma
CL
, Nguyen
CA
, Bronheim
R
, Kent
S
, Nadiger
S
, Pardo
D
, Halpern
SD
. Stability of end-of-life preferences: a systematic review of the evidence
. JAMA Intern Med
. 2014
;174
(7
):1085
–1092
.35.
Austin
CA
, Mohottige
D
, Sudore
RL
, Smith
AK
, Hanson
LC
. Tools to promote shared decision making in serious illness: a systematic review
. JAMA Intern Med
. 2015
;175
(7
):1213
–1221
.36.
Tinetti
ME
, Naik
AD
, Dindo
L
, et al. Association of patient priorities-aligned decision-making with patient outcomes and ambulatory health care burden among older adults with multiple chronic conditions: a nonrandomized clinical trial
. JAMA Intern Med
. 2019
;179
(12
):1688
-1697
.37.
Tinetti
ME
, Hashmi
A
, Ng
H
, et al. Patient priorities-aligned care for older adults with multiple conditions: a nonrandomized controlled trial
. JAMA Netw Open
. 2024
;7
(1
):e2352666
.38.
Barry
MJ
, Edgman-Levitan
S.
Shared decision making—pinnacle of patient-centered care
. N Engl J Med
. 2012
;366
(9
):780
-781
.39.
Klok
E
, Huisman
MV
. How I assess and manage the risk of bleeding during treatment of patients with venous thromboembolism
. Blood
. 2020
;135
(10
): 724
–734
.40.
Etxeandia-Ikobaltzeta
I
, Zhang
Y
, Brundisini
F
, et al. Patient values and preferences regarding VTE disease: a systematic review to inform American Society of Hematology guidelines
. Blood Adv
. 2020
;4
(5
):953
-968
.41.
Xarelto® (rivaroxaban). Prescribing information
. 2021
. Accessed 11
May
2021
. https://www.xareltohcp.com/nonvalvular-atrial-fibrillation/dosing.42.
Peterson
JJ
, Hoehns
JD
. Administration of direct oral anticoagulants through enteral feeding tubes
. J Pharm Technol
. 2016
;32
(5
):196
-200
.43.
Witt
DM
, Nieuwlaat
R
, Clark
NP
, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy
. Blood Adv
. 2018
;2
(22
):3257
-3291
.44.
Scott
IA
, Hilmer
SN
, Reeve
E
, et al. Reducing inappropriate polypharmacy: the process of deprescribing
. JAMA Intern Med
. 2015
;175
(5
):827
-834
.45.
46.
Ortel
TL
, Neumann
I
, Ageno
W
, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism
. Blood Adv
. 2020
;4
: 4693.Copyright © 2024 by The American Society of Hematology
2024
You do not currently have access to this content.
